Freyherr Intnl Group - Statement re. Suspension
RNS Number : 3796C
Freyherr International Group PLC
16 October 2020

Freyherr International Group plc


Statement Re: Suspension of Trading




The Board of Freyherr International Group plc ("Freyherr International" or '"the Company"), the medicinal cannabis group based in Slovenia, announces that it has requested the suspension of trading in its shares on the AQSE Growth Market. The Company's trading has been adversely affected by restrictions imposed in the UK and Slovenia as a result of the current Covid 19 pandemic and by the resignation of Tomaz Frelih and Luka Freyer as Directors.


It is also clear that the Company's audit (which requires visits to both the UK and Slovenian jurisdictions) cannot be completed until a free flow of personnel is possible between jurisdictions, which will place the Company is breach of AQSE Rules.  In the meantime, the Company is continuing to assess its financial position which is unclear following the departure of Messrs Frelih and Freyer. 


The Company will update the market in due course.


The directors of the issuer accept responsibility for the contents of this announcement

For further information please contact:





Tony Burke

Freyherr International Group plc

No.1 London Bridge

London SE1 9BG


020 7839 5081


Corporate Advisor

David Papworth

Level 17 Dashwood House

69 Old Broad Street





0207 101 7676


Note to Editors:

Freyherr International Group plc is the UK parent company of a group engaged in the production of medicinal cannabis, cannabis cultivation and the production of cannabis dosing and dispensing packaging. Operations are centred in Slovenia and the Group principally operates within the EU. The Group currently consists of 2 operating companies in Slovenia:

Freyherr Pharma d.o.o. is the analytics and pharmaceutical arm of the Group and holds an EU GMP certificate. It operates from its own certified building and manufactures CBD products for the Group and produces white label CBD products supplying them to various EU countries.


This information is provided by RNS, the news service of the . RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the use the personal data you provide us, please see our Privacy Policy.